← Back to Clinical Trials
Recruiting NCT04218344

NCT04218344 The Harefield Acute Myocardial Infarction Cohort

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04218344
Status Recruiting
Phase
Sponsor Royal Brompton & Harefield NHS Foundation Trust
Condition Acute Coronary Syndrome
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2020-01-09
Primary Completion 2030-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
60mls of blood donated for research analysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2020-01-09 with a primary completion date of 2030-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this project the investigator's plan to collect blood during a patient's routine angiogram procedure which they will have due to having suffered a heart attack. Data from the patients' routine procedures for this condition, including but not exclusively, ECG, Echocardiogram, MRI scans, will be collected. The aim of the research project is to analyse the blood samples and identify novel biomarkers and clinical parameters associated with acute coronary syndromes. The investigator's will particularly focus on markers of inflammation and micro-organism activity. The investigator's hope that this will help to gain more knowledge about what causes heart disease and how various conditions can be treated more efficiently. The investigator's will follow-up and collect further research data via a questionnaire at the routine 6 weeks and 6 months follow-up appointment after the angiogram procedure. Participants will also be telephoned at one-year post procedure, to update any events and medication status and data will thereafter be collected form data held by the hospital without having to contact the participant. Remaining blood samples will be stored securely for further analysis into blood and other markers.

Eligibility Criteria

Inclusion Criteria: • All patients presenting to Harefield Hospital through the Primary Percutaneous Coronary Intervention programme, with ST-segment elevation myocardial infarction, non ST-segment elevation myocardial infarction, unstable angina, Tako Tsubo syndrome, spontaneous coronary artery dissection and acute myocarditis, with the intention to assess with coronary angiography. Exclusion Criteria: * Patients will be able to self-exclude if they do not provide full informed consent * Every effort will be made to obtain informed consent from all patients. * Patients who do not survive the hospital episode will undergo a Professional or Personal Consultee process of assumed consent.

Frequently Asked Questions

Who can join the NCT04218344 clinical trial?

This trial is open to participants of all sexes, studying Acute Coronary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04218344 currently recruiting?

Yes, NCT04218344 is actively recruiting participants. Visit ClinicalTrials.gov or contact Royal Brompton & Harefield NHS Foundation Trust to inquire about joining.

Where is the NCT04218344 trial being conducted?

This trial is being conducted at Harefield, United Kingdom, Uxbridge, United Kingdom.

Who is sponsoring the NCT04218344 clinical trial?

NCT04218344 is sponsored by Royal Brompton & Harefield NHS Foundation Trust. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology